ABBISKO THERAPEUTICS
Abbisko Therapeutics is a drug company dedicated to innovative drug research and development. The company is founded by a group of seasoned drug hunters with rich research and managerial experience in top pharmaceutical companies globally and in China.
ABBISKO THERAPEUTICS
Industry:
Health Care Pharmaceutical Therapeutics
Founded:
2016-04-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.abbisko.com
Total Employee:
1+
Status:
Active
Total Funding:
263 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Content Delivery Network Font Awesome Apache Mobile Non Scaleable Content Microsoft Azure DNS Apple Mobile Web App Capable
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Alphamab Oncology
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization.
Blade Therapeutics
Blade Therapeutics is a discovery stage drug development company.
Exciva
German company is a provider of targeted drug rescue program intended to involve pharmaceutical research and development.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
LaNova Medicines
LaNova Medicines is a clinical-stage innovative drug research and development company.
Lucy Therapeutics
Lucy Therapeutics is a biotech company providing effective treatments for neurological diseases start with the mitochondria.
Silicon Therapeutics
Silicon Therapeutics is a fully integrated drug design, research, and development company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Shanghai Healthcare Capital
Shanghai Healthcare Capital investment in Series D - Abbisko Therapeutics
OrbiMed
OrbiMed investment in Series D - Abbisko Therapeutics
Temasek Holdings
Temasek Holdings investment in Series D - Abbisko Therapeutics
Warburg Pincus
Warburg Pincus investment in Series D - Abbisko Therapeutics
Janchor Partners
Janchor Partners investment in Series D - Abbisko Therapeutics
The Carlyle Group
The Carlyle Group investment in Series D - Abbisko Therapeutics
Lake Bleu Capital
Lake Bleu Capital investment in Series D - Abbisko Therapeutics
Hankang Capital
Hankang Capital investment in Series D - Abbisko Therapeutics
Qiming Venture Partners
Qiming Venture Partners investment in Series D - Abbisko Therapeutics
Greater Bay Area Homeland Development Fund
Greater Bay Area Homeland Development Fund investment in Series D - Abbisko Therapeutics
Official Site Inspections
http://www.abbisko.com Semrush global rank: 3.65 M Semrush visits lastest month: 3.88 K
- Host name: 47.243.71.197
- IP address: 47.243.71.197
- Location: San Mateo United States
- Latitude: 37.5517
- Longitude: -122.33
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94402
More informations about "Abbisko Therapeutics"
Abbisko Therapeutics - Crunchbase Company Profile
Abbisko Therapeutics is a drug company dedicated to innovative drug research and development. The company is founded by a group of seasoned drug …See details»
Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko …
22, November 2024, Shanghai – Abbisko Therapeutics Co., Ltd. (HKD：02256) today announced that the fir... ACoP 2024 ——Abbisko Therapeutics presents results o... Nov 13, 2024, …See details»
上海和誉生物医药科技有限公司 - Abbisko
港股上市公司和誉-b日前发布公告称，上海和誉医药自主研发的小分子抑制剂“匹米替尼”在治疗“腱鞘巨细胞瘤”的关键3期临床试验中，获得了积极顶线结果。See details»
Abbisko Therapeutics Co., Ltd. - Drug pipelines, Patents ... - Patsnap
Dec 31, 2024 About Abbisko Therapeutics Founded in April 2016, Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK), is an oncology-focused biopharmaceutical company based in …See details»
Abbisko Therapeutics - Overview, News & Similar companies
Who is Abbisko Therapeutics. Founded in April 2016, Abbisko Therapeutics Co., Ltd. is a biopharmaceutical company dedicated to discovering and developing innovative therapeutic s …See details»
Environmental, Social and Governance (ESG) Report - Abbisko
May 16, 2023 As a clinical-stage biopharmaceutical company, Abbisko is dedicated to the discovery and development of innova-tive and differentiated small molecule oncology …See details»
Abbisko Therapeutics - Funding, Financials, Valuation & Investors
Abbisko Therapeutics is registered under the ticker SEHK:2256 . Their stock opened with HK$12.46 in its Oct 13, 2021 IPO. Stock Symbol SEHK:2256 ; Valuation at IPO HK$8.8B; …See details»
Abbisko Therapeutics Co., Ltd. (上海和誉生物医药科技有限公司)
了解Abbisko Therapeutics Co., Ltd. (上海和誉生物医药科技有限公司)公司的药物管线，治疗领域，技术平台，以及它的45项临床试验, 43篇新闻和5篇文献，疾病领域:肿瘤，神经系统疾病， …See details»
Abbisko Therapeutics - Craft
Abbisko Therapeutics Summary. Company Summary. Overview. Abbisko Therapeutics is a company operating in drug research and development. The company embraces oncology, …See details»
Abbisko Therapeutics - Contacts, Employees, Board Members
Organization. Abbisko Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. ... Abbisko Therapeutics has 1 …See details»
Abbisko - Carlyle
Founded in April 2016, Abbisko is an oncology focused biopharmaceutical company dedicated to discover and develop innovative medicines for unmet medical needs in China and around the …See details»
Abbisko Therapeutics Announces Worldwide Collaboration with …
Jan 18, 2022 Abbisko Therapeutics is eligible to receive up to US$258 million in potential payments based on the achievement of prespecified preclinical, clinical development and …See details»
上海和誉生物医药科技有限公司-和誉医药在2024年欧洲肿瘤学会（…
2024年9月15日，和誉医药（港交所代码：02256）宣布，公司在2024年欧洲肿瘤学会（esmo）年会上公布其自主研发的小分子fgfr4抑制剂依帕戈替尼（absk011）在i期临床试验中针对fgf19 …See details»
Abbisko Cayman Limited (HKG: 2256) - Stock Analysis
Dec 31, 2024 Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule oncology therapies in Mainland China. The …See details»
Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Bioworld: …
Nov 13, 2024 The World Health Organization classifies TGCT as either localized or diffuse, with localized TGCT cases accounting for 80% to 90% of cases, and diffuse TGCT accounting for …See details»
Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko …
Jun 8, 2023 Abbisko Therapeutics has completed a Phase Ia dose escalation study for ABSK021 in the U.S. and is conducting an ongoing Phase Ib multi-cohort expansion trial in …See details»
上海和誉生物医药科技有限公司-和誉医药与艾力斯合作研发的新一 …
2024年9月24日，和誉医药（港交所代码：02256）公告表示，其独立发现并与艾力斯医药合作研发的新一代egfr口服小分子抑制剂abk3376，获得中国国家药品监督管理局（nmpa）批准进行 …See details»
Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko …
May 29, 2023 Abbisko Therapeutics published the preliminary Phase Ib results of ABSK021 for advanced TGCT in November 2022 at the 2022 Connective Tissue Oncology Society …See details»
Abbisko Therapeutics - 上海和誉生物医药科技有限公司-Abbisko …
Apr 25, 2024 Abbisko Therapeutics Announces Irpagratinib, an Innovative FGFR4 inhibitor,has been Granted ODD by the U.S. FDA for the Treatment of HCC. Apr 25,2024. By Abbisko . …See details»
上海和誉生物医药科技有限公司-智通财经：和 ... - Abbisko
美国罕见疾病组织(National Organization for Rare Disorders)报告指出，TGCT发病率约43/100万。 目前市场上竞品主要有第一三共的FIC产品Pexidartinib(培西达替尼)，其作为针对无法通过 …See details»